ALSEN.PA

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Biotechnology

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$19M	+255.9%	$-0.02	$-0.07–$0.09	—	4
2027	$4M	-80.8%	$-0.04	$-0.05–$-0.04	—	2
2028	$7M	+94.8%	$-0.02	$-0.02–$-0.02	—	1
2029	$133M	+1783.6%	$0.19	$0.17–$0.21	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 4 of the last 7 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-03-18	$-2.83	$-3.00	-5.8%
2025-09-22	$-2.50	$-2.50	+0.1%
2025-03-14	$-0.06	$-0.05	+9.1%
2024-09-18	$-3.00	$-3.00	-0.1%
2024-03-14	$-4.00	$-0.05	+98.8%
2023-09-20	$-7200.00	$-0.15	+100.0%
2023-06-07	$-0.11	$-7.00	-6263.6%

DCF fair valuemodel estimate

Intrinsic value

$0.07

Price

$0.22

Implied downside

-69%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
ALSEN.PASensorion S.A.	$0.22	-4.61%	$67M	—
ABNX.PAABIONYX Pharma S.A.	$1.69	-8.15%	$71M	—
ADOC.PAAdocia S.A.	$3.55	-2.80%	$71M	—
ALCJ.PACrossject S.A.	$1.31	-5.22%	$78M	—
ALGAE.PAFermentalg	$0.47	+1.29%

Sensorion S.A.

Sensorion SA is a clinical-stage biopharmaceutical firm based in Montpellier, France, specializing in the development of therapies for inner ear disorders. Their key initiatives include gene therapy programs: OTOF-GT, designed to restore hearing for individuals with Otoferlin deficiency, and USHER-T1-GT, targeting Usher syndrome Type 1. The company also advances SENS-401, a drug candidate for treating sudden sensorineural hearing loss. Sensorion's broader pipeline encompasses numerous experimental treatments aimed at restoring, treating, and preventing various conditions affecting the inner ear. They hold a collaboration agreement with Institut Pasteur concerning gene therapy for both pediatric and adult deafness. Additionally, Sensorion partners with Sonova Holding AG to integrate genetic analysis into the routine diagnosis of progressive adult hearing loss, combining advanced therapeutic approaches with traditional hearing aids. Founded in 2009, Sensorion SA operates primarily in France.

www.sensorion.com

Employees: 63
IPO / List date: Apr 21, 2015
HQ: FR

Held by traders on TradeandTell

No one on the platform currently holds ALSEN.PA.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in ALSEN.PA as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded ALSEN.PA yet.